Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2024 First Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no false
representations, misleading statements or material omissions contained in this announcement and
accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
Whether the first quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
The Reporting Period
Item YoY change (%)
(From January to March)
Revenues 4,339,814,452.16 -4.81
Net profit attributable to shareholders
439,798,106.55 -4.96
of the listed company
Net profit attributable to shareholders
of the listed company after deduction 427,753,549.19 -4.26
of extraordinary gains and losses
Net cash flow from operating activities 972,276,972.65 291.91
Basic earnings per share (RMB/share) 0.2357 -1.96
Diluted earnings per share
0.2355 -1.82
(RMB/share)
Weighted average return on net assets
3.15 Decreased by 0.34 percentage points
(%)
1 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Change as at the
end of the
As at the end of the As at the end of the Reporting Period
Reporting Period previous year as compared to
the end of the
previous year(%)
Total assets 36,462,147,240.89 36,358,126,258.82 0.29
Owner's equity attributable to
14,234,869,509.55 13,755,901,924.06 3.48
shareholders of the listed company
Notes: From January to March 2024, the Company Chemical pharmaceuticals realized revenues of RMB2,141
million, representing a YoY decrease of 4.86%, among which, RMB807 million were from gonadotropic
hormones, representing a YoY increase of 39.89%; RMB589 million were from gastroenterology products,
representing a YoY decrease of 25.68%; RMB417 million were from respiratory formulation products,
representing a YoY decrease of 18.17%; RMB135 million were from psychiatry products, representing a YoY
increase of 10.11%; and RMB115 million were from anti-infection products, representing a YoY decrease of
42.20%. APIs and intermediates products realized revenues of RMB1,399 million, representing a YoY decrease
of 3.70%. Traditional Chinese Medicine products realized revenues of RMB406 million, representing a YoY
decrease of 28.38%. Diagnostic reagents and equipment products realized revenues of RMB236 million from,
representing a YoY increase of 60.26%. Health care products realized revenues of RMB78 million, representing
a YoY increase of 96.50%. Biological products realized revenues of RMB44 million, representing a YoY
decrease of 29.86%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
For the
Item Explanation
Reporting Period
Gains and losses on disposal of non-current assets (including the Proceeds from disposal of
306,572.18
reversal of asset impairment provisions already recognized) fixed assets
Government grants recognized in profit and loss for current
Government grants through
period (except for government grants closely associated with
23,948,950.14 the profits and losses for the
corporate businesses, entitled at fixed amount or fixed level
Period
according to the national polices and standards)
Gains and losses on fair value changes incurred from financial Gains or losses arising from
assets held for trading, derivative financial assets, financial changes in fair value of
liabilities held for trading and derivative financial liabilities, and financial assets/liabilities
investment income on disposal of financial assets held for held for trading, and
3,385,577.72
trading, derivative financial assets, financial liabilities held for investment gains from
trading, derivative financial liabilities and other debt holding and disposal of
investments, except for effective hedging activities related to the financial assets/liabilities
ordinary operating business of the Company held for trading
Other non-operating income
Other non-operating income and expenses apart from the above
-3,998,396.15 and expenses excluding the
items
above items
Effect of the above items on
Less: Effect of income tax 1,860,588.22
income tax
The portion of the above
Effect of minority equity (after tax) 9,737,558.31 items to which minority
shareholders are entitled
Total 12,044,557.36
2 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Explanations for significant amount of extraordinary gain or loss items identified by the Company but not
listed in the “Explanatory Announcement No.1 for Public Company Information Disclosures –
Extraordinary Gains or Losses”, and recurring gain or loss items identified by the Company which are
listed as extraordinary gain or loss items in the “Explanatory Announcement No.1 for Public Company
Information Disclosures –Extraordinary Gains or Losses”.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
√Applicable □N/A
Item Change (%) Explanation
Net cash flow from Mainly due to the decrease in procurement
291.91
operating activities and expenses.
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons
Thereof
Unit: Yuan Currency: RMB
Change in
31 December
Balance Sheet 31 March 2024 proportion Main Reason
2023
（%）
Mainly due to the increase in the
Other receivables 62,309,748.02 46,010,624.61 35.42 receivables of export tax refund for the
Period.
Non-current assets Mainly due to the withdrawal of fixed-
273,390,415.52 406,376,425.44 -32.72
due within one year term deposits due within one year.
Mainly due to the new short-term cash
Other current assets 194,698,002.02 77,402,185.01 151.54
management business.
Other non-current Mainly due to the new medium to long-
1,446,707,336.74 957,224,255.77 51.14
assets term cash management business.
Mainly due to the repayment maturing
Short-term loans 1,360,009,625.00 2,076,159,347.22 -34.49
loans during the Period.
Financial liabilities Mainly due to changes in forward
4,654,285.13 86,817.12 5,261.02
held for trading foreign exchange contracts.
Mainly because part of the contract
payments received in advance in the
Contract liabilities 89,641,348.22 159,082,637.65 -43.65 Period which met the conditions for
revenue recognition were transferred to
revenues.
Employee benefits Mainly due to the payment of year-end
233,225,870.33 399,466,473.91 -41.62
payable bonuses to employees during the Period.
Non-current
Mainly due to the transfer of long-term
liabilities due within 1,397,628,656.81 718,564,144.31 94.50
borrowings due within one year.
one year
Mainly due to the fair value changes of
Other
other equity instrument investments and
comprehensive -22,278,942.52 -12,246,131.22 N/A
the impact of foreign currency
income
translation on financial statements.
Change in
January to January to
Income Statement proportion Main Reason
March 2024 March 2023
（%）
Mainly due to the increase in interest
Financial expenses -73,644,643.56 -15,861,425.43 N/A income from deposits for the Period as
compared with the previous period.
3 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Mainly due to the decrease in
Other income 35,611,817.69 54,191,288.49 -34.28 government grants for the Period as
compared with the previous period.
Mainly due to the receipt of dividend
Investment income 20,421,061.35 39,625,949.95 -48.47
payments in the previous period.
Gains from changes Mainly due to fluctuations in market
1,161,062.53 -27,478,190.74 N/A
in fair values value of the securities investment held.
Mainly due to aging changes of accounts
Losses of credit receivables resulting in the
-6,583,395.98 -15,459,174.59 N/A
impairment corresponding decrease in expected
credit loss during the Period.
Mainly due to the increase in the
Assets impairment impairment provision of inventories for
-4,077,243.26 1,837,691.27 -321.87
loss the Period as compared with the
previous period.
Mainly due to an increase in income
Non-operating
1,879,698.62 876,580.36 114.44 from disposal of scraps during the
income
Period.
Non-operating Mainly due to an increase in write-off
5,878,094.77 3,698,829.74 58.92
expenses losses of assets during the Period.
Change in
Cash Flow January to January to
proportion Main Reason
Statement March 2024 March 2023
（%）
Net cash flow from Mainly due to the decrease in
972,276,972.65 248,084,750.71 291.91
operating activities procurement and expenses.
Net cash flow from Mainly due to an increase in investment
-660,694,051.81 -71,511,309.54 N/A
investing activities payments for the Period.
Mainly due to the decrease in new
Net cash flow from
-894,822,792.10 -118,644,351.81 N/A borrowings and the increase in
financing activities
repayment of borrowings for the Period.
Effect of exchange Mainly due to changes in foreign
rate fluctuations on exchange rates resulting in a decrease in
4,074,463.63 -47,773,910.21 N/A
cash and cash exchange loss from foreign exchange
equivalents funds held.
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
Total number of holders of ordinary Total number of holders of preferred
shares as of the end of the Reporting 78,332 shares with restored voting rights as of 0
Period the end of the Reporting Period (if any)
Shareholdings of the top 10 shareholders
(excluding shares lent through refinancing business)
Number of Pledge, mark or lock-up
Nature of Number of Percentage shares held
Name of shareholder
shareholder shares held (%) with selling
restrictions Share
Number
status
Domestic non-
Shenzhen Baiyeyuan Investment Co.,
state-owned 895,653,653 47.98 0 Pledge 75,679,725
Ltd. (深圳市百业源投资有限公司)
legal person
Hong Kong Securities Clearing Company
Unknown 87,780,030 4.70 0 Unknown
Limited
4 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Foreign legal
Might Seasons Limited 35,929,699 1.92 0 Unknown
person
Perseverance Asset Management L.L.P–
Unknown 17,161,348 0.92 0 Unknown
Gaoyi Xiaofeng No. 2 Zhixin Fund
China Foreign Economy and Trade Trust
Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Unknown 16,677,148 0.89 0 Unknown
Hongyuan Collection Fund Trust Plan
Huaxia Life Insurance Co., Ltd. -
Unknown 12,729,218 0.68 0 Unknown
Proprietary
Foreign legal
Abu Dhabi Investment Authority 11,347,653 0.61 0 Unknown
person
CPIC Fund -China Pacific Life Insurance
Co., Ltd. -with-profit insurance-CPIC
Fund ChinaPacific Life Equity Relative Unknown 10,731,762 0.57 0 Unknown
Income (Guaranteed Dividend) single
assets management plan
Agricultural Bank of China Limited –CSI
500 Exchange Traded Index Securities Unknown 10,353,414 0.55 0 Unknown
Investment Fund
Joincare Pharmaceutical Group Industry
Co., Ltd. —the Third Phase Ownership
Scheme under Medium to Long-term Others 9,370,400 0.50 0 -
Business Partner Share Ownership
Scheme
Shareholdings of the top 10 shareholders without selling restrictions
Number of tradable shares held Class and number of shares
Name of shareholder
without selling restrictions Class of shares Number
Ordinary shares
Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
895,653,653 denominated in 895,653,653
投资有限公司) Renminbi
Ordinary shares
Hong Kong Securities Clearing Company Limited 87,780,030 denominated in 87,780,030
Renminbi
Ordinary shares
Might Seasons Limited 35,929,699 denominated in 35,929,699
Renminbi
Ordinary shares
Perseverance Asset Management L.L.P–Gaoyi Xiaofeng
17,161,348 denominated in 17,161,348
No. 2 Zhixin Fund
Renminbi
China Foreign Economy and Trade Trust Co., Ltd.–Foreign Ordinary shares
Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust 16,677,148 denominated in 16,677,148
Plan Renminbi
Ordinary shares
Huaxia Life Insurance Co., Ltd. -Proprietary 12,729,218 denominated in 12,729,218
Renminbi
Ordinary shares
Abu Dhabi Investment Authority 11,347,653 denominated in 11,347,653
Renminbi
CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-
Ordinary shares
profit insurance-CPIC Fund ChinaPacific Life Equity
10,731,762 denominated in 10,731,762
Relative Income (Guaranteed Dividend) single assets
Renminbi
management plan
Ordinary shares
Agricultural Bank of China Limited –CSI 500 Exchange
10,353,414 denominated in 10,353,414
Traded Index Securities Investment Fund
Renminbi
Joincare Pharmaceutical Group Industry Co., Ltd. —the Ordinary shares
Third Phase Ownership Scheme under Medium to Long- 9,370,400 denominated in 9,370,400
term Business Partner Share Ownership Scheme Renminbi
There was no connection or acting-in-concert relationship between
Description of connection or acting-in-concert relationship Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
of the above shareholders Company, and other shareholders; whether there is connection or acting-in-
concert relationship among other shareholders is unknown.
5 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Description of the participation of the top 10 shareholders
The participation of the top 10 shareholders and the top 10 shareholders
and the top 10 shareholders without selling restrictions in
without selling restrictions in securities lending and refinancing business is
margin financing and securities lending and refinancing
detailed in the table below.
business (if any)
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders
without selling restriction in securities lending transactions of refinancing business
√Applicable □N/A
Unit: shares
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction
in securities lending transactions of refinancing business
Number of shares lent through Number of shares lent through
Number of shares held in Number of shares held in
refinancing business and not yet refinancing business and not
ordinary and credit accounts at ordinary and credit accounts
Name of shareholder returned at the beginning of the yet returned at the end of the
the beginning of the Period at the end of the Period
(Full name) Period Period
Proportion Proportion Proportion Proportion
Total number Total number Total number Total number
(%) (%) (%) (%)
Agricultural Bank of
China Limited –CSI
500 Exchange Traded 5,055,774 0.27 1,509,200 0.08 10,353,414 0.55 801,600 0.04
Index Securities
Investment Fund
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities
lending/returning transactions of refinancing business compared to the previous period
√Applicable □N/A
Unit: shares
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities lending/returning
transactions of refinancing business compared to the previous period
Number of shares held by
Number of shares lent through shareholders in ordinary and credit
New / withdrawn
Name of shareholder (Full refinancing business and not yet accounts, and lent through
shareholdings
name) returned at the end of the Period refinancing business and not yet
during the Period
returned at the end of the Period
Total number Proportion (%) Total number Proportion (%)
Agricultural Bank of China
Limited –CSI 500 Exchange
New 801,600 0.04 11,155,014 0.60
Traded Index Securities
Investment Fund
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
6 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
7 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Consolidated Balance Sheet
31 March 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
Item 31 March 2024 31 December 2023
Current assets:
Cash and bank balances 15,118,198,045.39 15,691,888,314.83
Financial assets held for trading 88,627,684.77 82,899,154.24
Notes receivable 2,132,604,341.62 1,941,200,568.00
Accounts receivable 2,641,495,146.49 2,692,941,866.24
Receivables financing
Prepayments 320,528,020.48 280,102,860.94
Other receivables 62,309,748.02 46,010,624.61
Including: Interests receivable
Dividends receivable
Inventories 2,611,899,764.18 2,655,808,391.09
Contract assets
Assets Held-for-sale
Non-current assets due within one year 273,390,415.52 406,376,425.44
Other current assets 194,698,002.02 77,402,185.01
Total current assets 23,443,751,168.49 23,874,630,390.40
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investment 1,441,192,028.13 1,411,036,353.95
Other equity instrument investments 1,125,075,861.47 1,155,283,408.36
Other non-current financial assets
Investment properties 16,747,992.14 16,958,213.00
Fixed assets 5,599,470,118.92 5,664,352,555.97
Construction in progress 604,817,101.51 531,059,118.06
Productive biological assets
Oil and gas assets
Right-of-use assets 31,763,462.07 36,233,067.49
Intangible assets 680,629,773.47 683,337,333.73
Development expenditures 512,933,455.84 483,494,487.17
Goodwill 636,339,503.82 636,339,503.82
Long-term deferred expenses 338,816,538.46 328,642,740.95
Deferred income tax assets 583,902,899.83 579,534,830.15
Other non-current assets 1,446,707,336.74 957,224,255.77
Total non-current assets 13,018,396,072.40 12,483,495,868.42
Total assets 36,462,147,240.89 36,358,126,258.82
Current liabilities:
Short-term loans 1,360,009,625.00 2,076,159,347.22
Financial liabilities held for trading 4,654,285.13 86,817.12
Notes payable 1,709,979,271.07 1,469,148,287.38
Accounts payable 839,740,488.88 894,286,243.28
Receipts in advance
Contract liabilities 89,641,348.22 159,082,637.65
Employee benefits payable 233,225,870.33 399,466,473.91
Taxes payable 290,242,285.97 410,202,854.09
Other payables 3,894,003,172.09 3,682,604,038.73
Including: Interests payable
Dividends payable 11,458,767.63 12,478,280.13
8 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Liabilities held-for-sale
Non-current liabilities due within one year 1,397,628,656.81 718,564,144.31
Other current liabilities 46,181,338.66 51,087,001.83
Total current liabilities 9,865,306,342.16 9,860,687,845.52
Non-current liabilities:
Long-term loans 2,343,143,096.02 3,122,273,278.99
Bonds payable
Lease liabilities 11,556,383.03 15,422,948.41
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 362,705,046.07 370,179,550.82
Deferred income tax liabilities 252,778,619.58 260,032,144.44
Other non-current liabilities 90,000,000.00 90,000,000.00
Total non-current liabilities 3,060,183,144.70 3,857,907,922.66
Total liabilities 12,925,489,486.86 13,718,595,768.18
Owner's equity (or shareholder's equity):
Paid-in Capital (or Share capital) 1,866,634,764.00 1,865,523,807.00
Other equity instruments
Including: Preferred shares
Perpetual debts
Capital reserve 1,652,811,420.95 1,601,720,087.71
Less: Treasury shares
Other comprehensive income -22,278,942.52 -12,246,131.22
Special reserve
Surplus reserve 859,046,203.77 859,046,203.77
Undistributed profits 9,878,656,063.35 9,441,857,956.80
Total owner's equity (or shareholder's equity)
14,234,869,509.55 13,755,901,924.06
attributable to the parent company
Minority shareholder's equity 9,301,788,244.48 8,883,628,566.58
Total owner's equity (or shareholder's equity) 23,536,657,754.03 22,639,530,490.64
Total liabilities and owner's equity (or
36,462,147,240.89 36,358,126,258.82
shareholder's equity)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Guo Chenlu
9 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Consolidated Income Statement
From January to March, 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First quarter (January to First quarter (January to
Item
March) for 2024 March) for 2023
I. Total revenues 4,339,814,452.16 4,559,049,786.82
Including: Operating revenues 4,339,814,452.16 4,559,049,786.82
II. Total operating costs 3,296,136,273.86 3,563,214,097.57
Including: Operating costs 1,588,615,523.54 1,713,465,807.02
Operating tax and surcharges 46,715,949.27 54,610,788.80
Selling expenses 1,097,660,861.66 1,220,569,090.59
Administrative expenses 259,688,090.97 209,257,340.10
R&D expenses 377,100,491.98 381,172,496.49
Financial expenses -73,644,643.56 -15,861,425.43
Including: Interest expenses 33,732,578.57 33,036,361.57
Interest income 102,748,969.84 68,217,553.45
Add: Other income 35,611,817.69 54,191,288.49
Investment Income (“-” for loss) 20,421,061.35 39,625,949.95
Including: Income from investments
18,196,546.16 11,470,389.65
in associates and joint ventures
Gains from derecognition of
financial assets at amortized cost
Gains from net exposure hedges
(“-” for loss)
Gains from changes in fair values
1,161,062.53 -27,478,190.74
(“-” for loss)
Losses of credit impairment (“-” for
-6,583,395.98 -15,459,174.59
loss)
Assets impairment loss (“-” for
-4,077,243.26 1,837,691.27
loss)
Gains from disposal of assets (“-”
306,572.18
for loss)
III. Operating profit (“-” for loss) 1,090,518,052.81 1,048,553,253.63
Add: Non-operating income 1,879,698.62 876,580.36
Less: Non-operating expenses 5,878,094.77 3,698,829.74
IV. Total profit (“-” for loss) 1,086,519,656.66 1,045,731,004.25
Less: Income tax expenses 161,422,518.85 167,212,968.94
V. Net profit (“-” for loss) 925,097,137.81 878,518,035.31
(I) Classified by business continuity
1. Net profit from ongoing operation
925,097,137.81 878,518,035.31
(“-” for loss)
2. Net profit from discontinuing
operation (“-” for loss)
(II) Classified by ownership
1.Net profit attributable to
shareholders of the parent company 439,798,106.55 462,746,183.03
(“-” for loss)
2.Profit and loss of minority
485,299,031.26 415,771,852.27
shareholders (“-” for loss)
VI. Other comprehensive income, net of
-22,546,561.73 -83,671,573.75
tax
10 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
(I) Other comprehensive income
attributable to shareholders of the -10,032,811.30 -47,285,378.94
parent, net of tax
1. Other comprehensive income that
cannot be reclassified into profit or -10,449,421.02 -20,803,179.78
loss
(1) Changes from remeasurement of
defined benefit plans
(2) Other comprehensive income
that cannot be reclassified into profit or
loss under the equity method
(3) Changes in fair value of
-10,449,421.02 -20,803,179.78
investments in other equity instruments
(4) Changes in fair value of the
enterprise's own credit risks
2. Other comprehensive income that
416,609.72 -26,482,199.17
will be reclassified into profit or loss
(1) Other comprehensive income
that can be reclassified into profit or loss
under the equity method
(2) Changes in fair value of other
debt investments
(3) Amount of financial assets
reclassified into other comprehensive
income
(4) Provision for credit impairment
of other debt investments
(5) Reserve for cash flow hedges
(6) Exchange translation differences
on financial statements denominated in 416,609.72 -26,482,199.17
foreign currencies
(7) Others
(II) Other comprehensive income
attributable to minority shareholders, -12,513,750.43 -36,386,194.81
net of tax
VII. Total comprehensive income 902,550,576.08 794,846,461.55
(I) Total comprehensive income
attributable to owners of the parent 429,765,295.25 415,460,804.09
company
(II) Total comprehensive income
472,785,280.83 379,385,657.46
attributable to minority shareholders
VIII. Earnings per share:
(I) Basic earnings per share (RMB/share) 0.2357 0.2404
(II) Diluted earnings per share
0.2355 0.2398
(RMB/share)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Guo Chenlu
11 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Consolidated Cash Flow Statement
From January to March, 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First quarter First quarter
Item (January to (January to
March) for 2024 March) for 2023
I. Cash flow from operating activities:
Cash received from sales of goods and rendering of
4,476,359,723.04 4,361,096,155.32
services
Tax refunds received 22,324,907.54 40,439,680.21
Other cash received related to operating activities 138,196,959.28 202,829,024.01
Subtotal of cash inflow from operating activities 4,636,881,589.86 4,604,364,859.54
Cash paid for goods and services 1,141,145,195.81 1,563,463,357.75
Cash paid to and on behalf of employees 893,901,217.41 820,337,183.05
Payments of all types of taxes 613,555,586.00 541,191,286.96
Other cash paid related to operating activities 1,016,002,617.99 1,431,288,281.07
Subtotal of cash outflow in operating activities 3,664,604,617.21 4,356,280,108.83
Net cash flow from operating activities 972,276,972.65 248,084,750.71
II. Cash flow from investing activities:
Cash received from disposal of investment 70,031,257.75
Cash received from investment income 5,834,420.64 26,244,584.66
Net cash received from disposal of fixed assets, intangible
285,580.00 88,664.00
assets and other long-term assets
Net cash received from disposal of subsidiaries and other
business units
Other cash received related to investing activities 199,305,000.00 297,605,105.05
Subtotal of cash inflow from investing activities 205,425,000.64 393,969,611.46
Cash paid for purchase and construction of fixed assets,
248,170,722.58 244,675,030.69
intangible assets and other long-term assets
Cash paid to acquire investment 307,546,469.39 6,183,753.84
Net cash paid for acquisition of subsidiaries and other
12,461,951.59
business units
Other cash paid related to investing activities 310,401,860.48 202,160,184.88
Subtotal of cash outflow in investing activities 866,119,052.45 465,480,921.00
Net cash flow from investing activities -660,694,051.81 -71,511,309.54
III. Cash flow from financing activities:
Cash received from capital contribution 95,333,159.21
Including: Cash received from investment by minority
82,448,734.79
interests of subsidiaries
Cash received from borrowings 642,754,935.91 1,249,525,870.74
Other cash received related to financing activities 86,192.20
Subtotal of cash inflow from financing activities 738,174,287.32 1,249,525,870.74
Cash repayments of amounts borrowed 1,459,815,571.50 715,074,985.04
Cash payments for interest expenses and distribution of
39,274,885.57 41,156,153.68
dividends or profits
12 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
Including: Dividends and profit paid to minority interests
5,819,512.50 359,270.18
of subsidiaries
Other cash payments related to financing activities 133,906,622.35 611,939,083.83
Subtotal of cash outflow in financing activities 1,632,997,079.42 1,368,170,222.55
Net cash flow from financing activities -894,822,792.10 -118,644,351.81
IV. Effect of exchange rate fluctuations on cash and cash
4,074,463.63 -47,773,910.21
equivalents
V. Net increase in cash and cash equivalents -579,165,407.63 10,155,179.14
Add: Opening balance of cash and cash equivalents 15,340,869,372.73 14,178,465,686.40
VI. Closing balance of cash and cash equivalents 14,761,703,965.10 14,188,620,865.54
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Guo Chenlu
13 / 14
Joincare Pharmaceutical Group Industry Co., Ltd. 2024 First Quarterly Report
(III) Implementation of new accounting standards or interpretations of standards, for the first time from
2024 involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
25 April, 2024
14 / 14
